000710.SZ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 10:04):

Stats
Dzisiejszy wolumen	26.95M
Średni wolumen	20.52M
Kapitalizacja rynkowa	3.08B
EPS	CNY-0.113 ( 2023-10-27 )
Następna data zysków	( CNY0 ) 2024-05-17
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-7.70
ATR14	CNY0.0150 (0.17%)

Wolumen Korelacja

Długi: 0.40 (neutral)

Krótki: -0.84 (strong negative)

Signal:(54.736) Neutral

Berry Genomics Co.,Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Berry Genomics Co.,Ltd Korelacja - Waluta/Towar

-0.26
( neutral )

-0.11
( neutral )

0.00
( neutral )

-0.14
( neutral )

0.37
( neutral )

Berry Genomics Co.,Ltd Finanse

Annual	2023
Przychody:	CNY1.15B
Zysk brutto:	CNY515.20M (44.74 %)
EPS:	CNY-1.210

FY	2023
Przychody:	CNY1.15B
Zysk brutto:	CNY515.20M (44.74 %)
EPS:	CNY-1.210

FY	2022
Przychody:	CNY1.37B
Zysk brutto:	CNY584.36M (42.72 %)
EPS:	CNY-0.710

FY	2021
Przychody:	CNY1.42B
Zysk brutto:	CNY636.21M (44.73 %)
EPS:	CNY-0.310

Financial Reports:

No articles found.

Berry Genomics Co.,Ltd

Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.